69 related articles for article (PubMed ID: 2276222)
1. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report.
Labrie F; Dupont A; Bélanger A; Lacourcière Y; Béland L; Cusan L; Lachance R
Clin Invest Med; 1990 Oct; 13(5):275-8. PubMed ID: 2276222
[TBL] [Abstract][Full Text] [Related]
2. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
5. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
6. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
[TBL] [Abstract][Full Text] [Related]
7. Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effects.
Neri B; Bartalucci S; Pieri A; Gemelli MT; Rizzo M; Bartoletti R; Trippitelli A; Paoletti MC
Anticancer Res; 1989; 9(1):13-6. PubMed ID: 2495750
[TBL] [Abstract][Full Text] [Related]
8. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
Labrie F; Dupont A; Cusan L; Gomez JL; Diamond P
Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
[TBL] [Abstract][Full Text] [Related]
9. Aminoglutethimide as second line therapy in advanced breast cancer.
Elomaa I; Blomqvist C; Rissanen P
Breast Cancer Res Treat; 1986; 7 Suppl():S51-4. PubMed ID: 3017481
[TBL] [Abstract][Full Text] [Related]
10. Is aminoglutethimide an alternative to adrenalectomy for metastatic carcinoma of the breast?
Sterns EE; Bird CE; Mackie KW
Can J Surg; 1982 Nov; 25(6):695-7. PubMed ID: 7139430
[TBL] [Abstract][Full Text] [Related]
11. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
[TBL] [Abstract][Full Text] [Related]
13. Aminoglutethimide in the treatment of metastatic breast cancer.
Troner MB
Cancer Res; 1982 Aug; 42(8 Suppl):3402s-3404s. PubMed ID: 7083206
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
St-Arnaud R; Lachance R; Dupont A; Labrie F
Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
[TBL] [Abstract][Full Text] [Related]
15. Advances in the treatment of metastatic prostatic cancer.
Elder JS; Gibbons RP
West J Med; 1985 Sep; 143(3):342-5. PubMed ID: 2413632
[TBL] [Abstract][Full Text] [Related]
16. Newer methods of hormonal therapy for prostate cancer.
Soloway MS
Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
[TBL] [Abstract][Full Text] [Related]
17. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology.
Labrie F; Luu-The V; Labrie C; Simard J
Front Neuroendocrinol; 2001 Jul; 22(3):185-212. PubMed ID: 11456468
[TBL] [Abstract][Full Text] [Related]
18. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
20. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.
Harris AL; Powles TJ; Smith IE
Cancer Res; 1982 Aug; 42(8 Suppl):3405s-3408s. PubMed ID: 7083207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
